Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emeti...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Shimokawa
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Shimokawa1, T. Hayashi2, T. Kogawa3, R. Matsui4, K. Suzuki5, T. Saeki6, K. Aiba7, K. Tamura8
  • 1Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan, /
  • 2Department of Pharmacy, National Kyushu Medical Center, Fukuoka, Japan, /
  • 3Department of Developmental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan, /
  • 4Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan, /
  • 5Department of Pharmacy, The Cancer Institute Hospital of JFCR, Koto-ku, Japan, /
  • 6Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan, /
  • 7Division of Clinical Oncology/Hematology, The Jikei University School of Medicine, Minato-ku, Japan, /
  • 8General Medical Research Center, Fukuoka University, Fukuoka, Japan, /

Abstract

The incidence of delayed chemotherapy-induced nausea and vomiting (CINV) on colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy (FOLFOX/XELOX) has not been clearly controlled.